Latest research on Sitagliptin phosphate

Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.

Sitagliptin phosphate side effects

In a study published July 2014, Weir et al. further evaluated the effect of sitagliptin (Januvia) on cardiovascular endpoints (all-cause hospital admission/death as well as heart-failure-specific hospitalization/death in 7,620 diabetic patients recently diagnosed with heart failure) [146]. [source, 2015]
On the other hand, in the experiments with Sitagliptin phosphate there was a significant increase in LDH release when cells were incubated with concentrations above 2 mM (S1 Fig). [source, 2015]
The results obtained were in accordance with the results of LDH release, where concentrations above 2 mM of Sitagliptin phosphate caused a significant reduction in cell viability. [source, 2015]
The results showed a decrease in mitochondrial viability when cells were incubated with concentrations higher than 0.2 mM of Sitagliptin phosphate (S3 Fig). [source, 2015]
However, in the presence of Sitagliptin phosphate, SiHa cells showed a significant increase in migration, while for the HeLa cell line there was no significant change, indicating a possible relationship between DPPIV/CD26 enzyme activity and migration in these cells. [source, 2015]
The migration assay in presence of Sitagliptin phosphate suggests that the enzymatic activity of DPPIV/CD26 is associated with this process, considering that the inhibition of this activity, in SiHa cells, increased migratory capacity. [source, 2015]
Our results showed a significant decrease in cell adhesion when cells were treated with Sitagliptin phosphate. [source, 2015]
Regarding fasting lipid levels, both Sitagliptine and Pioglitazone had a similar impact on each of the parameters, with an increase in HDL-C and a decrease in the triglyceride levels. [source, 2013]